Last updated: October 25, 2026
Teduglutide is a specialty orphan drug marketed as Gattex in the United States and Revestive in Europe and other markets. Takeda owns the commercial franchise after acquiring Nycomed and later NPS Pharmaceuticals. The drug treats short bowel syndrome in adults and children who depend on parenteral support.
The commercial profile is defined by high annual treatment cost, a small but medically concentrated patient population, limited direct competition, and substantial barriers to manufacturing and clinical development. Takeda reports Gattex and Revestive as a combined product line. Reported sales have grown from a niche launch asset into a meaningful specialty-care franchise, with annual revenue measured in the high hundreds of millions of dollars when converted from yen.
What is teduglutide and how does it generate revenue?
Teduglutide is a recombinant analog of human glucagon-like peptide-2, or GLP-2. It is administered by subcutaneous injection once daily. The drug promotes intestinal mucosal growth and improves intestinal absorption, allowing some patients with short bowel syndrome to reduce or discontinue parenteral nutrition and intravenous fluids.[1]
| Commercial attribute |
Teduglutide |
| U.S. brand |
Gattex |
| International brand |
Revestive |
| Active ingredient |
Teduglutide |
| Drug class |
GLP-2 analog |
| U.S. application |
NDA 203441 |
| Initial U.S. approval |
December 2012 |
| Initial indication |
Adults with short bowel syndrome dependent on parenteral support |
| Pediatric approval |
Patients aged 1 year and older, approved in 2019 |
| Administration |
Once-daily subcutaneous injection |
| Primary commercial owner |
Takeda |
| Regulatory category |
Orphan drug; chemically synthesized recombinant peptide product |
Revenue comes primarily from chronic treatment of patients with intestinal failure. The economic value proposition is based on reduced parenteral nutrition use, fewer infusion-related complications, lower hospital utilization, and improved independence from central venous access.
How large is the teduglutide market?
The addressable market is small in patient count but large in revenue per patient. Short bowel syndrome is a rare disorder, and only a subset of patients require long-term parenteral support. That concentration allows a high-priced therapy to sustain a substantial franchise despite limited population volume.
Teduglutide’s market has several structural characteristics:
- Treatment is concentrated in specialist intestinal rehabilitation centers.
- Patients often require long-term therapy.
- Switching is limited because there are few approved pharmacologic alternatives.
- Reimbursement depends on documentation of parenteral nutrition dependence and disease severity.
- Treatment requires monitoring for gastrointestinal, biliary, pancreatic, fluid-retention, and neoplastic risks.[1]
- The product’s high price makes payer authorization and prior approval central to commercial access.
U.S. annual treatment cost is commonly reported in the hundreds of thousands of dollars per patient, although the net price varies by payer, dose, discounts, patient weight, and treatment duration. The label recommends a weight-based dose of 0.05 mg/kg once daily, which creates a direct relationship between patient size and product consumption.[1]
What is the financial trajectory of Gattex and Revestive?
Takeda reports Gattex and Revestive together rather than disclosing U.S. Gattex sales separately. The combined brand generated strong growth after Takeda integrated the NPS portfolio and expanded pediatric use.
| Fiscal period |
Reported commercial trend |
Main driver |
| 2012-2015 |
Early commercialization |
U.S. launch and specialist-center adoption |
| 2016-2019 |
Expansion |
Greater diagnosis, treatment-center penetration, and international rollout |
| 2019-2021 |
Accelerated demand |
Pediatric indication and continued penetration of parenteral-support patients |
| 2022-2024 |
Mature growth franchise |
Geographic expansion, treatment persistence, and higher recognition of intestinal rehabilitation economics |
Takeda’s annual reports place combined Gattex/Revestive revenue in the approximate ¥100 billion to ¥150 billion range in recent fiscal years, equivalent to roughly $700 million to $1 billion depending on exchange rates. Takeda’s fiscal 2023 report showed continued growth for the product line, while the company’s reporting structure did not identify a separate U.S. revenue figure.[2]
The franchise has several financial supports:
- High revenue per treated patient. A relatively small patient base can produce significant sales.
- Chronic use. Patients who respond may remain on treatment for extended periods.
- Limited substitution. Parenteral nutrition remains necessary for many patients, but competing approved drugs are limited.
- Specialist prescribing. Concentrated prescriber networks support targeted commercial investment.
- International growth. Revestive provides exposure outside the United States, particularly in European markets with established intestinal-failure programs.
Growth will moderate as major markets approach treatment-center saturation and as payers scrutinize long-term value. Future expansion depends more on diagnosis, pediatric uptake, and geographic penetration than on broad primary-care prescribing.
When does teduglutide lose market exclusivity?
Teduglutide’s principal regulatory exclusivity has expired. The original U.S. orphan-drug exclusivity period covered the adult short bowel syndrome indication for seven years after approval. Pediatric exclusivity later extended applicable exclusivity protection by six months.[3]
| Exclusivity category |
Key date or status |
| U.S. approval |
December 2012 |
| Seven-year orphan exclusivity |
Expired in 2019 |
| Pediatric exclusivity |
Added six months to applicable exclusivity periods |
| Small-molecule chemical exclusivity |
Expired |
| Patent protection |
Depends on the listed patent, claim scope, PTA, PTE, and litigation outcome |
| Biosimilar exclusivity |
Not applicable in the conventional monoclonal-antibody sense |
Loss of orphan exclusivity did not create an automatic generic launch. A competitor still needs an approved abbreviated new drug application, a suitable 505(b)(2) application, or another legally available pathway. The product’s peptide manufacturing process, injectable presentation, clinical comparability, and patent position remain practical barriers.
What patents protect teduglutide and Gattex?
The relevant U.S. protection is divided between composition, use, formulation, and product-specific regulatory listings. The FDA Orange Book should be treated as the controlling source for current listed patents and expiration data.[4]
Publicly associated teduglutide patent families include the following:
| Patent family or patent |
General subject matter |
Commercial relevance |
| U.S. Patent No. 8,110,532 |
GLP-2 analogs and related peptide subject matter |
Core composition and peptide protection |
| U.S. Patent No. 8,920,827 |
Teduglutide-related pharmaceutical composition or use claims |
Potential formulation or therapeutic coverage |
| U.S. Patent No. 9,266,951 |
GLP-2 analog therapeutic use claims |
Method-of-use protection |
| Related continuation and foreign families |
Peptide manufacture, treatment, and formulation claims |
Jurisdiction-specific barriers |
Patent expiration cannot be reduced to the earliest priority date. The operative date may include patent-term adjustment, pediatric extension, terminal disclaimers, and the particular claims asserted against a challenger. U.S. patent protection for the original teduglutide estate generally reaches into the mid-to-late 2020s, while later use or formulation claims may extend beyond the core composition term.
What formulations are protected by teduglutide patents?
Gattex is supplied as a lyophilized powder for reconstitution. Formulation and presentation claims can cover:
- Stabilized teduglutide compositions.
- Specified buffers and excipients.
- Lyophilized or reconstituted dosage forms.
- Storage and handling conditions.
- Pre-filled or alternative delivery systems, if separately claimed.
- Manufacturing processes that preserve peptide integrity and biological activity.
Formulation patents matter because a challenger may avoid a composition patent yet still infringe a listed formulation or method-of-use patent. They also affect the development of ready-to-use or reduced-burden presentations.
Are there Paragraph IV challenges to Gattex?
A Paragraph IV challenge requires a generic applicant to certify that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The certification can trigger patent litigation and a potential 30-month stay of FDA approval under the Hatch-Waxman framework.[5]
The public record does not show a widely reported, market-disruptive U.S. Paragraph IV challenge that has resulted in a generic teduglutide launch. This does not mean the product is immune from future ANDA activity. The commercial economics are attractive enough to support specialty-generic interest, but the opportunity is constrained by:
- Small patient population.
- Complex peptide characterization.
- Injectable manufacturing requirements.
- Potentially narrow product economics after discounts.
- Multiple patent categories.
- Risk of a lengthy regulatory review.
- Need to establish bioequivalence or clinical comparability for a peptide product.
A first successful ANDA applicant could receive 180-day generic exclusivity under the applicable statutory framework, creating a meaningful commercial advantage. The practical launch date would still depend on patent settlements, court decisions, regulatory approval, and any pediatric or regulatory exclusivity remaining in force.
What is the Orange Book status of Gattex?
Gattex is an approved NDA product and is eligible for Orange Book patent listing when its patents meet FDA listing requirements. The Orange Book is the key source for:
- Current listed patents.
- Patent use codes.
- Delisting events.
- Expiration dates.
- Pediatric extensions.
- Approved dosage forms and strengths.[4]
Orange Book listings do not establish that every listed patent will survive litigation. They identify patents that may create Hatch-Waxman certification and litigation risk. A generic applicant can challenge listed patents, carve out patented indications, or pursue a non-infringing label where legally available.
How strong is the teduglutide patent estate?
The estate is commercially strong but not impenetrable.
Strengths
- The product has a distinctive peptide sequence and mechanism.
- Core product protection was supported by orphan-drug exclusivity and patent rights.
- Method-of-use claims can cover treatment of a narrowly defined patient population.
- Formulation and manufacturing claims can complicate design-around strategies.
- The product is an injectable peptide rather than a conventional oral small molecule.
Weaknesses
- The original approval is more than a decade old.
- Orphan exclusivity has expired.
- Core composition protection is closer to expiration than newer specialty products.
- A generic may target only adult use or carve out pediatric and other protected indications.
- The market size may justify litigation for only a limited number of challengers.
- Patent validity risks increase when claims depend on predictable analog structures, known GLP-2 biology, or broad therapeutic language.
The most important commercial question is not simply whether one patent survives. It is whether a challenger can obtain approval with a commercially useful label before the remaining patent and regulatory barriers expire.
What patent litigation affects teduglutide?
Publicly visible litigation has not produced a major generic-entry event comparable to litigation involving large-volume drugs. The absence of a major launch preserves Takeda’s pricing position, but the risk profile will change if an ANDA filer identifies a viable pathway.
Potential litigation issues include:
- Whether the generic product infringes core peptide claims.
- Whether formulation claims cover the proposed injectable product.
- Whether method-of-use claims can be carved out.
- Whether listed patents are valid and enforceable.
- Whether Takeda can obtain a 30-month stay.
- Whether the parties reach a licensed or delayed-entry settlement.
Any settlement could establish an authorized-generic launch date, royalty terms, or restrictions on pediatric and adult indications. No broadly disclosed settlement has established a public early-entry date for a generic Gattex product.
Which companies are challenging or competing with teduglutide?
Teduglutide has no approved direct pharmacologic competitor with equivalent market status in the United States. Competition comes from three sources.
Parenteral nutrition and intestinal rehabilitation
Parenteral nutrition remains the standard supportive treatment for intestinal failure. Surgical reconstruction, bowel-lengthening procedures, dietary management, fluid optimization, and specialized rehabilitation programs can reduce dependence on intravenous support.
These approaches compete with teduglutide on total cost and clinical suitability. They do not offer a direct substitute for the drug’s intestinal trophic mechanism.
Pipeline GLP-2 therapies
Companies have developed longer-acting or potentially more convenient GLP-2 analogs. The principal strategic objectives are less frequent dosing, improved reduction in parenteral support, and easier administration.
| Pipeline direction |
Potential advantage over teduglutide |
| Long-acting GLP-2 analogs |
Weekly or less frequent dosing |
| Alternative peptide formulations |
Lower administration burden |
| Expanded intestinal-failure indications |
Larger eligible population |
| Improved stability or delivery |
Lower handling complexity |
Products such as apraglutide and glepaglutide have represented the most relevant development approaches, although clinical timelines, trial outcomes, and development status have changed over time.[6][7]
Generic or follow-on teduglutide
A follow-on product would compete primarily on price. Because the patient population is specialized, a generic could win share through payer substitution, hospital contracts, and specialty-pharmacy economics rather than through broad retail promotion.
Does teduglutide face biosimilar risk?
Traditional biosimilar risk is limited because teduglutide is a recombinant peptide rather than a large monoclonal antibody. A competitor would not generally enter through the same commercial model used for biosimilars of adalimumab, ustekinumab, or infliximab.
The more relevant risks are:
- An ANDA for a peptide product.
- A 505(b)(2) application.
- A clinical follow-on product with a modified formulation.
- A long-acting GLP-2 analog.
- A non-infringing product with a restricted label.
The regulatory pathway will depend on product structure, manufacturing method, reference-product classification, and FDA determination of the appropriate application route.[8]
What manufacturing and intellectual-property barriers protect the franchise?
Teduglutide requires peptide synthesis or recombinant production, purification, folding or structural control where applicable, sterile fill-finish, and analytical testing. Manufacturing risks include:
- Peptide impurity control.
- Aggregation and degradation.
- Potency and bioactivity testing.
- Batch consistency.
- Sterility assurance.
- Stability after reconstitution.
- Cold-chain and specialty distribution requirements.
These barriers are manageable for experienced peptide manufacturers but are more substantial than those for many standard oral generics. The principal commercial moat is therefore a combination of patents, regulatory complexity, specialist distribution, and limited patient volume rather than patents alone.
What is the regulatory status of Gattex and Revestive?
Gattex is FDA-approved for adults and pediatric patients aged 1 year and older with short bowel syndrome who are dependent on parenteral support.[1] Revestive is approved in the European Union for adult patients with short bowel syndrome after a period of intestinal adaptation.[9]
Key safety and monitoring requirements include:
- Colonoscopic evaluation because of the potential for accelerated growth of neoplastic tissue.
- Monitoring for intestinal obstruction.
- Monitoring for biliary and pancreatic disease.
- Management of fluid overload and electrolyte changes.
- Adjustment of parenteral nutrition and intravenous-fluid support.
- Pediatric surveillance for growth and disease-related complications.
The regulatory label supports chronic use but requires specialist oversight. This limits casual prescribing and reinforces the drug’s concentration in intestinal-failure centers.
What is the revenue exposure if generic entry occurs?
Takeda’s exposure is material because Gattex/Revestive is a durable specialty product with high revenue per patient. The impact of generic entry would depend on timing and penetration.
| Entry scenario |
Likely commercial effect |
| No entry before late-decade patent expiry |
Continued high gross-to-net revenue and stable specialist demand |
| One authorized generic |
Moderate price erosion; Takeda may retain patients through contracting |
| Multiple generics |
Sharp price erosion and payer-driven substitution |
| Long-acting branded competitor |
Slower volume loss but pressure on new starts and premium pricing |
| Pediatric carve-out or limited label |
Partial protection for Takeda’s treated population |
The first generic could capture a disproportionate share of new starts if payers mandate substitution. Existing patients may switch more slowly because treatment centers control initiation, titration, and monitoring.
How does teduglutide compare with competing rare-disease drugs?
Teduglutide has a narrower patient population than many rare-disease blockbusters but a stronger connection between treatment and measurable resource reduction.
| Factor |
Teduglutide |
Typical rare-disease specialty drug |
| Patient population |
Very small |
Small to moderate |
| Treatment setting |
Intestinal-failure specialist centers |
Often specialist or hospital |
| Administration |
Daily subcutaneous injection |
Varies |
| Revenue per patient |
Very high |
Often high |
| Direct competition |
Limited |
Often increasing |
| Generic risk |
Delayed by peptide and patent complexity |
Depends on modality |
| Payer focus |
Reduction in parenteral support and complications |
Disease-specific outcomes |
| Main commercial risk |
Generic entry or long-acting GLP-2 competitor |
Competition, pricing, and clinical differentiation |
Teduglutide’s economic case is strongest in patients with substantial parenteral nutrition dependence. Its value is weaker when patients require limited intravenous support or have contraindications to treatment.
Key takeaways
- Teduglutide is Takeda’s Gattex/Revestive franchise for short bowel syndrome with parenteral-support dependence.
- The product has generated sustained specialty-drug revenue, with combined sales in recent Takeda reporting periods in the approximate ¥100 billion to ¥150 billion range.
- U.S. orphan exclusivity has expired, but patents, pediatric protection, formulation claims, and regulatory complexity continue to delay generic entry.
- The commercial estate is protected by composition, use, formulation, manufacturing, specialist distribution, and clinical-monitoring barriers.
- No major public Paragraph IV-driven generic launch has disrupted the franchise.
- The primary future threats are a peptide follow-on product, a long-acting GLP-2 analog, or a successful ANDA supported by patent litigation.
- Revenue risk is meaningful because the product has high revenue per patient, but the franchise is insulated by a small, specialized treatment population and limited direct competition.
FAQs about teduglutide market and patent risk
What is the annual cost of Gattex treatment?
Annual treatment cost is generally in the several-hundred-thousand-dollar range before rebates and payer discounts. Actual cost depends on patient weight, dosing, coverage, and treatment duration.
Is teduglutide a biologic?
Teduglutide is a recombinant GLP-2 analog peptide. Its regulatory treatment differs from that of large monoclonal-antibody biologics, making conventional biosimilar analysis less applicable.
Can a generic copy Gattex without conducting large clinical trials?
A generic or follow-on applicant may avoid a full new-drug development program, but it must satisfy FDA requirements for the selected pathway. Peptide structure, formulation, manufacturing, and bioequivalence issues can require substantial analytical and clinical evidence.
Does pediatric approval extend Gattex patent life?
Pediatric exclusivity can add six months to qualifying patents or regulatory exclusivity periods. It does not create a new long-term patent term for every Gattex-related claim.
Which company originally developed teduglutide?
Teduglutide was developed through NPS Pharmaceuticals and licensed to Nycomed. Takeda acquired Nycomed in 2011 and acquired NPS Pharmaceuticals in 2015, consolidating rights to the product.
References
- U.S. Food and Drug Administration. (2024). Gattex (teduglutide) prescribing information.
- Takeda Pharmaceutical Company Limited. (2024). Annual report 2024.
- U.S. Food and Drug Administration. (2024). Drugs@FDA: Gattex application history and exclusivity information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2023). Hatch-Waxman amendments and abbreviated new drug applications.
- Zealand Pharma A/S. (2023). Annual report 2023.
- Ironwood Pharmaceuticals, Inc. (2023). Annual report 2023.
- U.S. Food and Drug Administration. (2022). Regulatory considerations for generic and follow-on peptide products.
- European Medicines Agency. (2024). Revestive: EPAR product information.
